Abstract
Background Modification of vaccination strategies is needed to improve the immune response to SARS-CoV-2 vaccination in kidney transplant recipients (KTRs).
Methods This multicenter observational study aimed to determine antibody kinetics among 60 seropositive KTRs and analyzed the effects of the third vaccination against SARS-CoV-2 in 174 previously seronegative KTRs. We investigated whether mycophenolate mofetil (MMF) dose reduction by 25-50% prior the third vaccination influences vaccination success.
Results 18 of 60 (30%) seropositive KTRs became seronegative in the serological assay within six months. Loss of antibodies was predicted by low initial antibody levels (≤206.8 BAU/ml), older age, and impaired graft function. A third vaccination in previously seronegative KTRs induced seroconversion in 56 of 174 (32.1%) KTRs with median antibody levels 119 (76–353) BAU/ml and median neutralizing capacity titer of 1:10 (0– 1:40). Multivariate logistic regression revealed that initial antibody levels (OR 1.39, 95% CI 1.09–1.76), graft function (OR 0.05, 95% CI 0.01–0.39), time after transplantation (OR 1.04, 95% CI 1.02–1.07) and MMF trough levels (OR 0.43, 95% CI 0.21–0.88) correlated with seroconversion, p<0.05. After controlling for these confounders, the effect of MMF dose reduction was calculated using propensity score matching. KTRs in the MMF reduction group had significantly lower MMF serum concentrations prior to the third vaccination and were more likely to develop antibody levels ≥35.2 BAU/ml than their matched KTRs (p=0.02).
Conclusions Temporary reduction in MMF dose might be a promising approach to improve the immune response in KTRs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Forschungskommission of the Medical Faculty, Heinrich-Heine-University Duesseldorf, the Ministry of Culture and Science of North Rhine-Westphalia (VIRus Alliance NRW) and BMBF (COVIM 01KX2021).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics committee of the Medical Faculty at the Heinrich-Heine University, Moorenstrasse 5, 40225 Duesseldorf, Germany (study numbers 2020-1237).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available at: doi:10.17632/g3wpr3xtpx.1
